GGHC
LKFT

Gilder Gagnon Howe & Co’s Lakefront Biotherapeutics American Depositary Shares LKFT Stock Holding History

Gilder Gagnon Howe & Co’s Portfolio LKFT Stock Details LKFT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-585,870
Closed -$23.9M – 254
2015
Q3 		$23.9M Sell
585,870
-180,082
-24% -$10.4M 0.38% 66
2015
Q2 		$39.4M Buy
+765,952
New +$40.6M 0.52% 54

Other funds holding LKFT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return

Gilder Gagnon Howe & Co's LKFT Position: Q4 2015 in Review

Gilder Gagnon Howe & Co sold out of Lakefront Biotherapeutics American Depositary Shares (LKFT) in Q4 2015, closing a stake of 585,870 shares — an estimated $23.9M sold.

Gilder Gagnon Howe & Co first reported a position in LKFT in Q2 2015 and held it in 2 quarters. The position peaked at $39.4M in Q2 2015. 44 funds tracked by Wall St. Rank hold LKFT as of Q4 2015.

  • Gilder Gagnon Howe & Co reported no remaining Lakefront Biotherapeutics American Depositary Shares position as of Q4 2015 after selling out during the quarter.
  • Gilder Gagnon Howe & Co sold 585,870 Lakefront Biotherapeutics American Depositary Shares shares in Q4 2015, an estimated $23.9M.
  • Gilder Gagnon Howe & Co first reported a position in Lakefront Biotherapeutics American Depositary Shares in Q2 2015 and held it in 2 quarters.
  • Gilder Gagnon Howe & Co's Lakefront Biotherapeutics American Depositary Shares position peaked at $39.4M in Q2 2015.
  • 44 funds tracked by Wall St. Rank held Lakefront Biotherapeutics American Depositary Shares as of Q4 2015.

Based on Gilder Gagnon Howe & Co's 13F filing for Q4 2015, filed 4 Feb 2016.